A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single Agent Maintenance

Protocol: SWOG – S2209

SCHEMA S2209

Please Note:  Below is a brief list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 or (810)762-8038, to discuss the full list of eligibility.

Eligibility:

1. Participants must have documented multiple myeloma satisfying standard International Myeloma Working Group (IMWG).
2. Participants must have measurable disease.
3. Participants must not have received any prior systemic therapy for multiple myeloma with the exception of any one or more of the following:                                                                                        1. An emergency use of a short course of corticosteroids (equivalent of
   dexamethasone 160 mg) any time before registration, or
   2. Up to one complete cycle of a non-daratumumab and hyaluronidase-fihj
   containing anti-myeloma regimen (1 cycle = 21 or 28 days depending on
   the regimen being used), or
   3. Localized palliative radiation therapy for multiple myeloma, as long as
   the radiation therapy is completed at least 3 days prior to starting the
   systemic treatment as per the study protocol.
4. Participants must have an ECOG/Zubrod performance status score of 0-2.
5. Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen.